Cure of Disseminated Human Lymphoma with [(225)Ac]Ac-Ofatumumab in a Preclinical Model

Immunotherapies that target the CD20 protein expressed on most non-Hodgkin lymphoma cells have improved clinical outcomes, but relapse is common. We prepared (225)Ac-labeled anti-CD20 ofatumumab and evaluated its in vitro characteristics and therapeutic efficacy in a murine model of disseminated hum...

Descripción completa

Detalles Bibliográficos
Autores principales: Longtine, Mark S., Shim, Kyuhwan, Hoegger, Mark J., Benabdallah, Nadia, Abou, Diane S., Thorek, Daniel L.J., Wahl, Richard L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2023
Materias:
Basic Science Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241019/
https://www.ncbi.nlm.nih.gov/pubmed/37024304
http://dx.doi.org/10.2967/jnumed.122.265167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241019/
https://www.ncbi.nlm.nih.gov/pubmed/37024304
http://dx.doi.org/10.2967/jnumed.122.265167

Ejemplares similares